Rule 8.1- Cambridge Antibody

RNS Number:4789D
AstraZeneca PLC
24 May 2006


                                                                        FORM 8.1

          DEALINGS BY OFFERORS, OFFEREE COMPANIES OR THEIR ASSOCIATES

                  FOR THEMSELVES OR FOR DISCRETIONARY CLIENTS

      (Rules 8.1(a) and (b)(i) of the City Code on Takeovers and Mergers)


1.         KEY INFORMATION


Name of person dealing (Note 1)                AstraZeneca UK Limited
Company dealt in                               Cambridge Antibody Technology Group plc
Class of relevant security to which the        Ordinary Shares
dealings being disclosed relate (Note 2)

Date of dealing                                23 May 2006



2.         INTERESTS, SHORT POSITIONS AND RIGHTS TO SUBSCRIBE



(a)        Interests and short positions (following dealing) in the class of
relevant security dealt in (Note 3)


                                                                 Long                              Short


                                               Number                           Number
                                                                 (%)                              (%)

(1) Relevant securities                        15,896,267*     29.9%

(2) Derivatives (other than options)


(3) Options and agreements to purchase/sell


Total                                          15,896,267*     29.9%


*This includes 1,400 ordinary shares and 200 ADSs held by Goldman, Sachs & Co.,
and 76,684 shares held by Deutsche Bank AG, both of whom are deemed to be acting
in concert with AstraZeneca UK Limited, purchased prior to the commencement of
the Offer Period.



(b)        Interests and short positions in relevant securities of the company,
other than the class dealt in (Note 3)


Class of relevant security:                                  Long                              Short


                                               Number                           Number
                                                             (%)                              (%)

(1) Relevant securities


(2) Derivatives (other than options)


(3) Options and agreements to purchase/sell


Total


(c)        Rights to subscribe (Note 3)


Class of relevant security:                    Details









3.         DEALINGS (Note 4)



(a)        Purchases and sales


Purchase/sale                          Number of securities                  Price per unit (Note 5)

Purchase                               5,600,000                             1,320 pence


(b)        Derivatives transactions (other than options)


Product name,         Long/short (Note 6)       Number of securities (Note 7)        Price per unit (Note 5)

e.g. CFD


(c)        Options transactions in respect of existing securities

(i)         Writing, selling, purchasing or varying


Product name,         Writing, selling, Number of securities  Exercise   Type, e.g.      Expiry     Option money
                        purchasing,     to which the option              American,
e.g. call option      varying etc.      relates (Note 7)      price      European etc.   date       paid/received per
                                                                                                    unit (Note 5)


(ii)        Exercising


Product name, e.g. call option         Number of securities                  Exercise price per unit (Note 5)



(d)        Other dealings (including new securities) (Note 4)


Nature of transaction (Note 8)         Details                               Price per unit (if applicable) (Note 5)




4.         OTHER INFORMATION



Agreements, arrangements or understandings relating to options or derivatives




Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating
to the voting rights of any relevant securities under any option referred to on this form or relating to the voting
rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is
referenced.  If none, this should be stated.

None



Is a Supplemental Form 8 attached? (Note 9)                       NO


Date of disclosure                                                24 May 2006

Contact name                                                      Keith Darlington

Telephone number                                                  020 7304 5000

Name of offeree/offeror with which associated                     AstraZeneca UK Limited
Specify category and nature of associate status (Note 10)         Offeror


Notes


The Notes on Form 8.1 can be viewed on the Takeover Panel's website at
www.thetakeoverpanel.org.uk


                      This information is provided by RNS
            The company news service from the London Stock Exchange
END

DCCSEIEDDSMSEII